Veraxa Biotech Holding AG
Limited financial coverage for VRXA.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.
- CEO
- Christoph Antz
- IPO
- 2026
- Employees
- 8
- HQ
- Heidelberg, ZH, DE
Get TickerSpark's AI analysis on VRXA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- 52W High
- $27.36
- 52W Low
- $1.04
- 50D MA
- $1.63
- 200D MA
- $7.87
- Beta
- 0.26
- RSI (14)
- 25
- Avg Volume
- 290.42K
No earnings-call transcripts are available for VRXA yet.
- Free Float
- 8.9%
- Shares Outstanding
- 141.41M
- Float Shares
- 12.61M
Our VRXA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on VRXA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
globenewswire.com · Sep 4
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
globenewswire.com · Jul 29
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
globenewswire.com · Jul 27
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
globenewswire.com · Jul 27
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
globenewswire.com · Jul 24
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
globenewswire.com · Jul 23
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
globenewswire.com · Jul 20
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
globenewswire.com · Jul 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.